Jardiance vs Farxiga: SGLT2 Inhibitor Head-to-Head

✓ Medically reviewed by  ·  Last reviewed: May 2026

Morgan Ellis

Pharmacy Researcher · 8 years experience

Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.

Jardiance vs Farxiga: SGLT2 Inhibitor Head-to-Head

Last updated: June 27, 2026

Quick Answer: Jardiance (empagliflozin) and Farxiga (dapagliflozin) are the two most-prescribed SGLT2 inhibitors in the world and they are clinically very similar — both lower HbA1c by ~0.6–0.8%, produce ~2–3 kg weight loss, and have positive cardiovascular and renal outcome data. The clinically meaningful differences are subtle: Jardiance has the stronger mortality signal (EMPA-REG OUTCOME), Farxiga the broadest CKD evidence (DAPA-CKD enrolled non-diabetics), and Farxiga the lower starting price. For most patients, choosing between them is more about access and cost than meaningful clinical difference. This guide gives the full comparison.

Farxiga vs Jardiance: The Same Question, Reversed

Search interest splits almost evenly between “Jardiance vs Farxiga” and “Farxiga vs Jardiance” — it is the same head-to-head either way round. Jardiance is the global brand name for empagliflozin (Boehringer Ingelheim). Farxiga is the US brand name for dapagliflozin (AstraZeneca); the identical molecule is sold as Forxiga in the UK, EU, and most of the rest of the world. So whether you searched Farxiga or Forxiga, Jardiance-first or Farxiga-first, the comparison below is the one you want: empagliflozin versus dapagliflozin, the two dominant SGLT2 inhibitors.

Same Mechanism, Different Molecules

Both drugs are selective inhibitors of sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubule. SGLT2 normally reabsorbs ~90% of filtered glucose. Inhibition causes 50–100 g of glucose to be excreted daily in the urine — independent of insulin — producing osmotic diuresis (small natriuresis and water loss), modest caloric loss (200–400 kcal/day), and a measurable reduction in arterial pressure.

Empagliflozin (Jardiance)

Approved 2014. Highest SGLT2 selectivity in the class (>2600-fold over SGLT1). Half-life 12.4 hours; once-daily dosing. Manufactured by Boehringer Ingelheim. WHO-GMP generic available as Jardiance (Empagliflozin); combination products include Glyxambi (empagliflozin + linagliptin).

Dapagliflozin (Farxiga / Forxiga)

Approved 2014 (EU) / 2014 (US). High SGLT2 selectivity (~1200-fold). Half-life ~12.9 hours; once-daily dosing. Manufactured by AstraZeneca. WHO-GMP generic available as Forxiga (Dapagliflozin).

Head-to-Head Comparison

Dosing and Titration: The One Real Practical Difference

The clearest practical distinction between the two is the dosing ceiling. Jardiance comes in 10 mg and 25 mg tablets — the 25 mg dose offers a little extra glucose-lowering, although its landmark cardiovascular and kidney benefits (EMPA-REG, EMPA-KIDNEY) were established at 10 mg. Farxiga is effectively a single-strength drug for outcomes: 10 mg once daily (a 5 mg starting option exists, mainly for tolerability), and every major Farxiga outcome trial used 10 mg.

Both are taken once daily, with or without food, and there is no need to time them around meals the way you would a sulfonylurea. Morning dosing is usually preferred simply because the mild diuretic effect can otherwise add to night-time urination. Neither requires blood-glucose-guided titration — you start at the standard dose and stay there.

Kidney function guides initiation more than the choice between the two molecules. As eGFR falls, the glucose-lowering effect of both drugs fades (less glucose is filtered to be excreted), but their cardiovascular and kidney-protective effects persist well into chronic kidney disease. Current labelling allows initiation at lower eGFR thresholds than the original 2014 approvals — baseline kidney function and volume status should be checked before starting either one.

The Outcome Trials — Where the Differences Live

EMPA-REG OUTCOME (Jardiance, 2015)

The first cardiovascular outcome trial of an SGLT2 inhibitor changed diabetes management overnight. 7,020 Type 2 diabetics with established CVD randomised to empagliflozin or placebo. Results:

• −14% in three-point MACE (cardiovascular death, non-fatal MI, non-fatal stroke)
• −38% in cardiovascular death — driven almost entirely by reduced HF mortality and sudden death
• −35% in hospitalisation for heart failure
• −39% in worsening nephropathy

DECLARE-TIMI 58 (Farxiga, 2019)

17,160 Type 2 diabetics with established CVD OR multiple risk factors. Lower-risk population than EMPA-REG. Results:

• Co-primary MACE: not significantly different (HR 0.93, p=0.17)
• Co-primary CV death + HHF: −17% (driven by HHF)
• −27% in hospitalisation for heart failure
• −24% renal composite endpoint

DECLARE’s “softer” MACE result reflects the lower baseline CV risk in its enrolled population, not weaker drug effect.

DAPA-HF and DAPA-CKD: Farxiga’s Expansion Beyond Diabetes

Research spotlight: DAPA-HF (2019, NEJM) randomised 4,744 patients with HFrEF (EF ≤40%), with or without diabetes, to dapagliflozin or placebo. Composite of worsening HF or CV death reduced 26%. DAPA-CKD (2020, NEJM) randomised 4,304 CKD patients, with or without diabetes, to dapagliflozin or placebo. Composite of ≥50% eGFR decline, ESRD, or death reduced 39%. Both trials made dapagliflozin the first SGLT2 inhibitor approved in non-diabetic HF and non-diabetic CKD. Empagliflozin (EMPEROR-Reduced, EMPEROR-Preserved, EMPA-KIDNEY) followed with comparable data, but Farxiga’s earlier non-diabetic indications are why some clinicians still default to it for that use case.

Fixed-Dose Combination Pills: Jardiance Has More Options

If you are likely to need more than one diabetes drug, the breadth of fixed-dose combinations is a genuine point of difference — and here empagliflozin has the wider menu:

• Jardiance combinations: Glyxambi (empagliflozin + linagliptin, a DPP-4 inhibitor), Synjardy (empagliflozin + metformin), and Trijardy XR (empagliflozin + linagliptin + metformin — a genuine three-in-one tablet).
• Farxiga combinations: Xigduo XR (dapagliflozin + metformin) and Qtern (dapagliflozin + saxagliptin).

For someone already on metformin who wants to cut pill count, both brands offer a metformin combination. The difference shows up at the next step: Jardiance’s Trijardy collapses three mechanisms into one tablet, whereas the dapagliflozin range tops out at two-drug combinations. Fixed-dose pills improve adherence but reduce dosing flexibility, so they suit patients already stable on the individual components.

Where Treatment Guidelines Put Them

Major guidelines no longer treat SGLT2 inhibitors as just another glucose-lowering option — they are recommended for organ protection in their own right. The American Diabetes Association’s Standards of Care, the heart-failure guidelines from the ESC, and the kidney guidelines from KDIGO all advise an SGLT2 inhibitor for people with Type 2 diabetes who also have established cardiovascular disease, heart failure, or chronic kidney disease — independent of HbA1c and regardless of whether metformin is already on board. In heart failure and CKD, the indication now extends to people without diabetes at all. Crucially, the guidelines frame this as a class recommendation: both empagliflozin and dapagliflozin qualify, which is why choosing between Jardiance and Farxiga usually comes down to the phenotype-specific and cost considerations covered above rather than any guideline preferring one over the other.

When to Choose Which

The honest answer: For most patients, either drug is fine. The class effect is dominant; molecule-specific differences are subtle. Use whichever is more affordable, more available, or already in your formulary. Where differences matter:

Prefer Jardiance (Empagliflozin) If:

• You have established cardiovascular disease + Type 2 diabetes and CV mortality reduction is the priority — EMPA-REG showed −38% CV death; DECLARE was neutral on CV death
• You want the longest cardiovascular outcome dataset
• You have HFpEF — EMPEROR-Preserved was the first trial to show clear benefit in this phenotype

Prefer Farxiga (Dapagliflozin) If:

• You have HFrEF without diabetes — DAPA-HF was the first SGLT2 trial in non-diabetic HF and remains the strongest evidence base for this group
• You have CKD without diabetes — DAPA-CKD has the strongest non-diabetic CKD evidence
• Cost or access is meaningfully better for Farxiga in your market
• You have lower-risk Type 2 diabetes where MACE prevention isn’t the priority

Avoid Both If:

• You have Type 1 diabetes — significantly increased DKA risk; only approved with caution as adjunct in select populations
• You have severe CKD with eGFR < 20 (initiation thresholds vary; once eGFR drops below 20 mL/min/1.73 m² on therapy, continuation is acceptable; new initiation usually paused)
• You have a history of recurrent UTIs, genital fungal infections, or severe Fournier’s gangrene risk
• You are pregnant or planning pregnancy — neither is recommended

Drug Interactions and Sick-Day Rules

SGLT2 inhibitors have a clean interaction profile — they are not metabolised through the major CYP enzyme pathways that cause most drug-drug problems — but two combinations need attention, and both apply equally to Jardiance and Farxiga:

• Diuretics: added to a loop or thiazide diuretic, an SGLT2 inhibitor compounds fluid loss. Your diuretic dose may need to be reviewed — and often reduced — especially if you are elderly.
• Insulin and sulfonylureas: SGLT2 inhibitors rarely cause hypoglycaemia on their own, but stacked on insulin or a sulfonylurea (such as glimepiride) the combined glucose-lowering can tip you low. Doses of those agents are often trimmed when an SGLT2 is added.

Sick-day rule: pause the drug during any acute illness that stops you eating and drinking normally — vomiting, diarrhoea, fever, or before surgery — because dehydration raises the risk of euglycaemic ketoacidosis. The common mnemonic is to hold “SADMANS” medicines when acutely unwell; the final “S” is your SGLT2 inhibitor. Restart only once you are eating and drinking normally again.

Class-Wide Side Effects (Both Drugs)

Common

• Genital mycotic infections — 5–10% of women, 1–3% of men; higher in uncircumcised men. Most respond to topical antifungals; rarely necessitate stopping the drug.
• UTI — slightly increased rate; manage standardly
• Volume depletion symptoms — light-headedness on standing, dizziness, mild dehydration; matters most in elderly or on diuretics
• Polyuria/nocturia — typical, usually settles after 4–6 weeks

Uncommon but Important

• Euglycaemic DKA — rare in T2DM; higher risk during fasting, alcohol use, low-carb diets, surgery. Pause drug 3 days before elective surgery; restart only when eating normally.
• Fournier’s gangrene — extremely rare necrotising fasciitis of the perineum; FDA warning issued 2018. Total reported cases globally remain low.
• Lower limb amputation — signal seen in CANVAS for canagliflozin; not seen in empagliflozin or dapagliflozin trials. Class label retains a caution.

What to Expect: Treatment Timeline

• Day 1: glucose excretion in the urine begins almost immediately — this is why both drugs can mildly increase urination and thirst in the first weeks.
• Weeks 1–4: a small drop in blood pressure and the start of fluid and weight loss; early genital-itch or thrush symptoms, if they occur, usually appear in this window.
• Week 12: the full HbA1c effect (roughly −0.6 to −0.8%) is measurable — the usual point to recheck.
• Month 6 and beyond: weight loss plateaus around 2–3 kg; the cardiovascular and kidney-protective benefits accrue gradually over months to years of continuous use, which is why staying on therapy matters more than which of the two you chose.

Generic Pricing Has Closed the Gap

Both drugs have generic versions available in many global markets. WHO-GMP empagliflozin and dapagliflozin from manufacturers like Sun Pharma, Cipla, and Dr Reddy’s are typically $15–$40 per month — a fraction of the $600+ branded US price. In markets where both generics are available, the price difference between Jardiance and Farxiga generics is usually under 20%, making clinical fit the more important selection factor.

How They Fit With Other Diabetes Drugs

• Foundation: Metformin (Diabetes Starter Pack) — see Jardiance vs Metformin
• Layered classes:
  • SGLT2 — Jardiance / Farxiga (this article)
  • GLP-1 — semaglutide; see Ozempic vs Metformin
  • DPP-4 — sitagliptin; see Januvia vs Metformin
  • Sulfonylurea — glimepiride; see Glimepiride vs Metformin
  • TZD — pioglitazone; see Pioglitazone vs Metformin
• For patients with cardiovascular disease or heart failure: SGLT2 + GLP-1 + metformin is becoming the standard “triple-mechanism” backbone

Frequently Asked Questions

Are Jardiance and Farxiga interchangeable?

Clinically very close — same mechanism, similar HbA1c effect, similar weight loss, similar BP reduction. The subtle differences (Jardiance’s CV mortality edge, Farxiga’s non-diabetic HF/CKD priority) matter for specific phenotypes. For routine Type 2 diabetes management, either is acceptable.

Can I switch between them?

Yes — start the new drug the day after stopping the old one. No washout needed. Monitor as you would normally.

What about the third SGLT2 inhibitor, Invokana (canagliflozin)?

Canagliflozin has positive CV and renal outcome data (CANVAS, CREDENCE) but also showed a small increase in lower-limb amputations not seen with empagliflozin or dapagliflozin. Most clinicians now prefer Jardiance or Farxiga as first-choice SGLT2 inhibitors. Invokana remains in use, particularly for renal indications.

Do I need to drink more water on SGLT2 inhibitors?

Yes — they cause modest diuresis. Maintain regular fluid intake. The volume-depletion signal is highest in elderly patients on loop diuretics; your loop diuretic dose may need to be reduced after starting an SGLT2.

Will an SGLT2 inhibitor protect my kidneys?

Yes — both have strong evidence for slowing CKD progression in Type 2 diabetes (EMPA-KIDNEY, DAPA-CKD), and Farxiga additionally has strong evidence in non-diabetic CKD. The mechanism appears to be reduction of glomerular hyperfiltration via tubuloglomerular feedback.

Can I take SGLT2 inhibitors with metformin?

Yes — extensively co-prescribed. Both lower HbA1c independently and the combination is one of the best-evidenced T2DM regimens for patients with cardiovascular or renal risk. Glyxambi (Glyxambi) is a related fixed-dose option (empagliflozin + linagliptin).

Is Farxiga or Jardiance better for weight loss?

Neither has a meaningful edge. Both produce about 2–3 kg of weight loss over the first year through urinary calorie loss — useful but modest, and far less than a GLP-1 agonist such as semaglutide. If weight is the main goal rather than cardiovascular or kidney protection, an SGLT2 inhibitor is not the most powerful tool.

Which is cheaper, Jardiance or Farxiga?

Branded prices are similar (roughly $600–$650 a month in the US). Where it matters is generics: WHO-GMP empagliflozin and dapagliflozin are typically $15–$40 a month, and the gap between the two generics is usually small. Local availability tends to decide the price more than the molecule does.

Should I take Jardiance or Farxiga in the morning or at night?

Either works — both are once-daily and food-independent. Most people take their SGLT2 inhibitor in the morning so the mild increase in urination does not disturb sleep. Day-to-day consistency matters more than the exact time.

Bottom line: Jardiance (empagliflozin) and Farxiga (dapagliflozin) are far more alike than different. Lean Jardiance when reducing cardiovascular death in established heart disease is the priority, or for HFpEF; lean Farxiga for heart failure or chronic kidney disease in people without diabetes, or when it is simply cheaper to access. For everyday Type 2 diabetes, pick whichever your formulary and budget favour and stay on it — the class benefit is what protects your heart and kidneys.

Medical Disclaimer: SGLT2 inhibitor selection should be based on individual cardiovascular and renal profile, comorbidities, and side-effect tolerance. Baseline eGFR, volume status, and infection-risk assessment are advised before initiation. Always work with a qualified healthcare provider for therapy decisions.

Written by

Sophie Chen

Pharmaceutical Content Researcher · 8 years experience

Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.